Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
Autor: | Aida Emirova, Dave Singh, Marie Anna Nandeuil, Mirco Govoni, Henrik Watz, Brian Leaker, Oliver Kornmann, Silvia Geraci, Germano Lucci, Kai Michael Beeh, Brendan Colgan |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Male medicine.medical_specialty Chronic bronchitis Leukotriene B4 Placebo Gastroenterology 03 medical and health sciences chemistry.chemical_compound Pulmonary Disease Chronic Obstructive 0302 clinical medicine Double-Blind Method Internal medicine medicine para-Aminobenzoates Humans Induced sputum Macrophage inflammatory protein Aged lcsh:RC705-779 Inflammation Pharmacology COPD Sulfonamides Cross-Over Studies Dose-Response Relationship Drug business.industry Research Chronic obstructive pulmonary disease Sputum lcsh:Diseases of the respiratory system Middle Aged medicine.disease Crossover study Phosphodiesterase 4 inhibitors Bronchodilator Agents 030104 developmental biology Treatment Outcome 030228 respiratory system chemistry Tumor necrosis factor alpha Female medicine.symptom Inflammation Mediators business Biomarkers |
Zdroj: | Respiratory Research Respiratory Research, Vol 20, Iss 1, Pp 1-12 (2019) |
ISSN: | 1465-993X |
Popis: | Background CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). Methods This was a multicentre, three-period (each 32 days), three-way, placebo-controlled, double-blind, complete-block crossover study. Eligible patients had COPD, chronic bronchitis, and were receiving inhaled triple therapy for ≥2 months. Patients received CHF6001 800 or 1600 μg, or matching placebo twice daily via multi-dose dry-powder inhaler (NEXThaler). Induced sputum was collected pre-dose on Day 1, and post-dose on Days 20, 26 and 32. Blood was sampled pre-dose on Day 1, and pre- and post-dose on Day 32. Results Of 61 randomised patients, 54 (88.5%) completed the study. There were no significant differences between groups for overall sputum cell count, or absolute numbers of neutrophils, eosinophils or lymphocytes. CHF6001 800 μg significantly decreased the absolute number and percentage of macrophages vs placebo. In sputum, compared with placebo both CHF6001 doses significantly decreased leukotriene B4, C-X-C motif chemokine ligand 8, macrophage inflammatory protein 1β, matrix metalloproteinase 9, and tumour necrosis factor α (TNFα). In blood, both CHF6001 doses significantly decreased serum surfactant protein D vs placebo. CHF6001 1600 μg significantly decreased TNFα ex-vivo (after incubation with lipopolysaccharide). Conclusion The data from this study show that CHF6001 inhaled twice daily has anti-inflammatory effects in the lungs of patients with COPD already treated with triple inhaled therapy. Trial registration The study is registered on ClinicalTrials.gov (NCT03004417). Electronic supplementary material The online version of this article (10.1186/s12931-019-1142-7) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |